These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 22315336

  • 21. Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in healthy adults: A phase I/II, observer-blind, randomized, controlled trial.
    Madan A, Ferguson M, Sheldon E, Segall N, Chu L, Toma A, Rheault P, Friel D, Soni J, Li P, Innis BL, Schuind A.
    Vaccine; 2017 Mar 07; 35(10):1431-1439. PubMed ID: 28187952
    [Abstract] [Full Text] [Related]

  • 22. Evaluation of immune response following one dose of an AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or older.
    Ikematsu H, Tenjinbaru K, Li P, Madan A, Vaughn D.
    Hum Vaccin Immunother; 2012 Aug 07; 8(8):1119-25. PubMed ID: 22854661
    [Abstract] [Full Text] [Related]

  • 23. A randomised, partially observer blind, multicentre, head-to-head comparison of a two-dose regimen of Baxter and GlaxoSmithKline H1N1 pandemic vaccines, administered 21 days apart.
    Nicholson KG, Abrams KR, Batham S, Clark TW, Hoschler K, Lim WS, Medina M, Nguyen-Van-Tam JS, Read RC, Warren FC, Zambon M.
    Health Technol Assess; 2010 Dec 07; 14(55):193-334. PubMed ID: 21208550
    [Abstract] [Full Text] [Related]

  • 24. Immunogenicity and safety of an AS03(A)-adjuvanted H5N1 influenza vaccine in a Taiwanese population.
    Hwang SJ, Chang SC, Yu CJ, Chan YJ, Chen TJ, Hsieh SL, Lai HY, Lin MH, Liu JY, Ong G, Roman F, Dramé M, Bock HL, Yang PC.
    J Formos Med Assoc; 2011 Dec 07; 110(12):780-6. PubMed ID: 22248833
    [Abstract] [Full Text] [Related]

  • 25. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.
    Nassim C, Christensen S, Henry D, Holmes S, Hohenboken M, Kanesa-Thasan N.
    Pediatr Infect Dis J; 2012 Apr 07; 31(4):e59-65. PubMed ID: 22418661
    [Abstract] [Full Text] [Related]

  • 26. Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial.
    Rümke HC, Richardus JH, Rombo L, Pauksens K, Plaßmann G, Durand C, Devaster JM, Dewé W, Oostvogels L.
    BMC Infect Dis; 2013 Jul 26; 13():348. PubMed ID: 23890405
    [Abstract] [Full Text] [Related]

  • 27. Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children.
    Knuf M, Leroux-Roels G, Rümke H, Rivera L, Pedotti P, Arora AK, Lattanzi M, Kieninger D, Cioppa GD.
    Hum Vaccin Immunother; 2015 Jul 26; 11(2):358-76. PubMed ID: 25621884
    [Abstract] [Full Text] [Related]

  • 28. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.
    Fukase H, Furuie H, Yasuda Y, Komatsu R, Matsushita K, Minami T, Suehiro Y, Yotsuyanagi H, Kusadokoro H, Sawata H, Nakura N, Lattanzi M.
    Vaccine; 2012 Jul 13; 30(33):5030-7. PubMed ID: 22472791
    [Abstract] [Full Text] [Related]

  • 29. Flexibility of interval between vaccinations with AS03A-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18-60 and >60 years: a randomized trial.
    Duval X, Caplanusi A, Laurichesse H, Deplanque D, Loulergue P, Vaman T, Launay O, Gillard P.
    BMC Infect Dis; 2012 Jul 23; 12():162. PubMed ID: 22824474
    [Abstract] [Full Text] [Related]

  • 30. Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies.
    Garcia-Sicilia J, Arístegui J, Omeñaca F, Carmona A, Tejedor JC, Merino JM, García-Corbeira P, Walravens K, Bambure V, Moris P, Caplanusi A, Gillard P, Dieussaert I.
    Hum Vaccin Immunother; 2015 Jul 23; 11(10):2359-69. PubMed ID: 26176592
    [Abstract] [Full Text] [Related]

  • 31. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial.
    Jackson LA, Campbell JD, Frey SE, Edwards KM, Keitel WA, Kotloff KL, Berry AA, Graham I, Atmar RL, Creech CB, Thomsen IP, Patel SM, Gutierrez AF, Anderson EL, El Sahly HM, Hill H, Noah DL, Bellamy AR.
    JAMA; 2015 Jul 21; 314(3):237-46. PubMed ID: 26197184
    [Abstract] [Full Text] [Related]

  • 32. Dose-range study of MF59-adjuvanted versus nonadjuvanted monovalent A/H1N1 pandemic influenza vaccine in six- to less than thirty-six-month-old children.
    Block SL, Ruiz-Palacios GM, Guerrero ML, Beygo J, Sales V, Holmes SJ.
    Pediatr Infect Dis J; 2012 Jul 21; 31(7):e92-8. PubMed ID: 22481427
    [Abstract] [Full Text] [Related]

  • 33. Impact of pre-existing immunity on the induction of functional cross-reactive anti-hemagglutinin stalk antibodies following vaccination with an AS03 adjuvanted pandemic H1N1 vaccine.
    Tete SM, Jul-Larsen Å, Rostami S, Lunde THF, Søland H, Krammer F, Cox RJ.
    Vaccine; 2018 Apr 12; 36(16):2213-2219. PubMed ID: 29548607
    [Abstract] [Full Text] [Related]

  • 34. A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations.
    Hatz C, Cramer JP, Vertruyen A, Schwarz TF, von Sonnenburg F, Borkowski A, Lattanzi M, Hilbert AK, Cioppa GD, Leroux-Roels G.
    Vaccine; 2012 Jul 06; 30(32):4820-7. PubMed ID: 22626675
    [Abstract] [Full Text] [Related]

  • 35. Immunogenicity and Safety of an EB66 Cell-Culture-Derived Influenza A/Indonesia/5/2005(H5N1) AS03-Adjuvanted Vaccine: A Phase 1 Randomized Trial.
    Schuind A, Segall N, Drame M, Innis BL.
    J Infect Dis; 2015 Aug 15; 212(4):531-41. PubMed ID: 25722291
    [Abstract] [Full Text] [Related]

  • 36. Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults.
    Madan A, Segall N, Ferguson M, Frenette L, Kroll R, Friel D, Soni J, Li P, Innis BL, Schuind A.
    J Infect Dis; 2016 Dec 01; 214(11):1717-1727. PubMed ID: 27609809
    [Abstract] [Full Text] [Related]

  • 37. Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study.
    Díez-Domingo J, Garcés-Sanchez M, Baldó JM, Planelles MV, Ubeda I, JuBert A, Marés J, Moris P, Garcia-Corbeira P, Dramé M, Gillard P.
    Pediatr Infect Dis J; 2010 Jun 01; 29(6):e35-46. PubMed ID: 20375709
    [Abstract] [Full Text] [Related]

  • 38. Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials.
    Launay O, Duval X, Fitoussi S, Jilg W, Kerdpanich A, Montellano M, Schwarz TF, Watanveerade V, Wenzel JJ, Zalcman G, Bambure V, Li P, Caplanusi A, Madan A, Gillard P, Vaughn DW.
    BMC Infect Dis; 2013 Sep 16; 13():435. PubMed ID: 24041010
    [Abstract] [Full Text] [Related]

  • 39. Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine.
    Cheong HJ, Song JY, Heo JY, Noh JY, Choi WS, Park DW, Wie SH, Kim WJ.
    Clin Vaccine Immunol; 2011 Aug 16; 18(8):1358-64. PubMed ID: 21715575
    [Abstract] [Full Text] [Related]

  • 40. Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: pooled analysis of 28 clinical trials.
    Vaughn DW, Seifert H, Hepburn A, Dewe W, Li P, Drame M, Cohet C, Innis BL, Fries LF.
    Hum Vaccin Immunother; 2014 Aug 16; 10(10):2942-57. PubMed ID: 25483467
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.